Sugi Predict
/ Targets
/ DDRGK1
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to DDRGK1 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Weight Loss Study: Genetics and Response to Naltrexone/Bupropion |
PHASE4 | RECRUITING |
| Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency |
PHASE2/PHASE3 | RECRUITING |
| The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus |
PHASE3 | UNKNOWN |
| I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations |
PHASE2 | COMPLETED |
| Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma |
PHASE2 | RECRUITING |
| Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer |
PHASE1/PHASE2 | COMPLETED |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies |
PHASE1/PHASE2 | RECRUITING |
| Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors |
PHASE1/PHASE2 | RECRUITING |
| Study Of ATRN-119 In Patients With Advanced Solid Tumors |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| Pembrolizumab (MK-3475) in MM Patients With Residual Disease |
PHASE2 | COMPLETED |
| Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma |
PHASE1/PHASE2 | COMPLETED |
| Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies |
PHASE1 | COMPLETED |
| Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases |
PHASE1 | COMPLETED |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma |
PHASE1 | COMPLETED |
| A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial |
PHASE1 | RECRUITING |
| Prognostic Biomarkers in Patients With Urothelial Carcinoma |
nan | COMPLETED |
| Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma |
nan | COMPLETED |
| Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment |
nan | NOT_YET_RECRUITING |
| Genetic Study of Age-Related Macular Degeneration |
nan | COMPLETED |
| Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA |
nan | RECRUITING |
| Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer |
nan | ACTIVE_NOT_RECRUITING |
| Autophagy in Systemic Lupus Erythematosus |
nan | UNKNOWN |
| Association of Autophagy-related Genes ,LncRNA and SNPs With Colorectal Cancer in Egyptian Population |
nan | COMPLETED |
| Biomarker Research in Inherited Movement Disorders |
nan | RECRUITING |
Related proteins — ESM-2 sequence neighbours (a DDRGK1 binder may also engage these)